Vanguard Group Inc. raised its position in shares of Pulse Biosciences, Inc (NASDAQ:PLSE) by 49.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 267,810 shares of the company’s stock after buying an additional 88,902 shares during the period. Vanguard Group Inc. owned about 1.88% of Pulse Biosciences worth $9,247,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nationwide Fund Advisors acquired a new stake in shares of Pulse Biosciences during the second quarter worth approximately $177,000. Rhumbline Advisers bought a new position in Pulse Biosciences in the second quarter valued at approximately $325,000. New York State Common Retirement Fund bought a new position in Pulse Biosciences in the second quarter valued at approximately $338,000. Schwab Charles Investment Management Inc. bought a new position in Pulse Biosciences in the second quarter valued at approximately $529,000. Finally, Teachers Advisors LLC bought a new position in Pulse Biosciences in the second quarter valued at approximately $566,000. 9.35% of the stock is owned by institutional investors.
Shares of Pulse Biosciences, Inc (NASDAQ PLSE) traded up $0.31 during mid-day trading on Friday, reaching $23.19. 92,045 shares of the company’s stock were exchanged, compared to its average volume of 187,885. Pulse Biosciences, Inc has a 1 year low of $5.20 and a 1 year high of $39.50.
Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.52) earnings per share (EPS) for the quarter.
In related news, major shareholder Robert W. Duggan acquired 2,000,000 shares of the company’s stock in a transaction that occurred on Sunday, September 24th. The shares were acquired at an average cost of $15.02 per share, for a total transaction of $30,040,000.00. Following the completion of the acquisition, the insider now directly owns 5,797,612 shares in the company, valued at approximately $87,080,132.24. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mitchell E. Levinson acquired 3,835 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The shares were bought at an average price of $12.30 per share, for a total transaction of $47,170.50. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 2,466,429 shares of company stock worth $36,893,301. Insiders own 6.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Vanguard Group Inc. Acquires 88,902 Shares of Pulse Biosciences, Inc (PLSE)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://ledgergazette.com/2017/12/11/vanguard-group-inc-raises-holdings-in-pulse-biosciences-inc-plse.html.
About Pulse Biosciences
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Receive News & Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.